CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Ege David S. sold 5,012 shares at $7.93 ($39,745)
- 4 Grant or award Chief Financial Officer acquired 42,500 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 8,738,243 shares at $3.15 ($27,525,465)
- 4 Grant or award Chief Legal Officer and EVP acquired 63,492 shares (grant or award)
- 4 Grant or award Henn Matthew R. acquired 47,619 shares (grant or award)
- 4 Grant or award Cloghessy Paula acquired 31,746 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 63,492 shares (grant or award)
- 4 Grant or award Director acquired 63,492 shares (grant or award)
- 4 Grant or award Ege David S. acquired 31,746 shares (grant or award)
- 4 Grant or award Director acquired 31,746 shares (grant or award)
Page 8 of 19 · 380 filings